3月5日,全球临床试验收录网站clinicaltrials显示,安进启动了AMG 133(Maridebart Cafraglutide,MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2),标志着AMG 133进入III期开发阶段。MARITIME-1MARITIME-1是一项随机、双盲、安慰剂对照临床试验(n=3501),旨在评估AMG 133(低中高剂量)在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.